Curosurf

Curosurf (Poractant Alfa) is a surfactant replacement therapy used to treat respiratory distress in premature infants. This product aids in lung function by reducing surface tension, facilitating breathing. Manufactured by Chiesi Farmaceutici S.P.A., it is essential for neonatal intensive care units.

Curosurf is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the infant's lungs lack sufficient surfactant, a substance that keeps the air sacs open. By administering Curosurf, healthcare providers aim to improve lung function and ease breathing. The therapy is administered via endotracheal tube, directly into the lungs.

Curosurf works by replacing the natural surfactant in the lungs, which helps to reduce surface tension and prevent the collapse of alveoli. This action can lead to improved oxygenation and reduced need for mechanical ventilation. Common effects include stabilization of lung function and improved respiratory status in premature infants.

Curosurf should be administered by trained healthcare professionals in a controlled medical setting. Proper handling and storage are crucial to maintain its efficacy. It is important to follow the manufacturer's guidelines for administration and monitor the infant's response closely. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf is generally used in a controlled medical environment, minimizing the risk of interactions with other medications. However, healthcare providers should be aware of any concurrent therapies the infant may be receiving. Always inform your healthcare provider about all medications and treatments the infant is undergoing to ensure safe and effective use.